|Day Low - High||0.38 - 0.41|
|Year Low - High||0.32 - 3.97|
More Healthcare/Biotech NewsAugust 2, 2017
Health Insurance Innovations, Inc. (HIIQ) Reports Record Q2 Results & Revises Upward!May 3, 2017
Health Insurance Innovations (HIIQ) Reports Record Q1’17 Revenue & Revises Full-Year Guidance UpwardApril 25, 2017
Affordable Health Insurance Provider Health Insurance Innovations (HIIQ) To Report Q1 Results & Host Conference Call May 3April 19, 2017
Two Emerging Growth Firms Surged +40% Today!March 1, 2017
Affordable Health Insurance Administrator Health Insurance Innovations Reports Record 2016 RevenueFebruary 23, 2017
The Diabetic EpidemicFebruary 20, 2017
Johnson & Johnson Acquires European Biotech Giant Actelion For $30 Billion | Zero Hedge
Approximately one in eight women will be diagnosed with breast cancer during their lifetime. Every two minutes an American woman is diagnosed with breast cancer; 40,000 die each year. Tamoxifen has been widely used for over 30 years for breast cancer. Additional research has shown that it is the metabolites of tamoxifen, of which endoxifen is the most active, that have potential therapeutic value.
Atossa is the only company in the WORLD attempting to conquer breast cancer the way they are and have stated “The best way to treat a disease is to prevent it in the first place.” They are developing a topical drug, a lotion applied to each breast, to treat a condition known as high breast density. Third-party studies have shown that high breast density increases the risk of developing breast cancer in some women. Breast density is diagnosed by mammography and approximately 10 million women have high density in the U.S. Tamoxifen has been demonstrated to reduce density and the incidence of breast cancer. However, tamoxifen can have serious side effects because, as a drug taken orally, it is delivered “systemically” meaning it travels throughout the body to other areas the drug is not needed. The goal with their topical endoxifen program is to treat high breast density with a local, topical drug.
Atossa is also developing a new way to deliver pharmaceuticals – through microcatheters (small tubes that can be inserted with anesthetic, through the nipple) so that pharmaceuticals can be targeted to the tissue where breast cancer actually grows.
Their proprietary oral and topical forms of endoxifen are the subject of a comprehensive Phase 1 clinical study in healthy women in Australia. Their patented microcatheter technology is in a Phase 2 clinical study that is also currently enrolling patients.
Let’s Catch Up! Read Vista Partners Weekly Market Update for Week Ending August 18, 2017
Vista Partners new Weekly Market Update for Week Ending August 18, 2017 includes a quick overview & results of the markets for the week written by Managing Director John F. Heerdink, Jr. and news, trending videos from Vista Partners Coverage Universe that includes all components
CEO Of Atossa Genetics (NasdaqCM: ATOS) Stated: “We have reached an important milestone!”
Steve Quay, President, and CEO of Atossa Genetics (NasdaqCM: ATOS) a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions stated: “We have reached an important milestone by completing enrollment in both the topical and oral arms
Catch Up with Vista Partners Weekly Market Update for Week Ending August 11, 2017
Happy Weekend All! Vista Partners has published its Weekly Market Update for Week Ending August 4, 2017, which includes a quick overview of the results of the markets for the week written by Managing Director John F. Heerdink, Jr., news, trending videos from Vista Partners